Haydar Frangoul, MD, on Clinically Meaningful and QoL Improvements in Sickle Cell With Exa-Cel


The Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute discussed new data from CLIMB-121 presented at ASH 2023 supporting Casgevy's approval.

“Across the board, all the quality of life measures we measured showed significant improvement over time. And that's a lot to be said for a product that is using your own cells, not somebody else's cells, and hopefully would be available for every patients with sickle cell disease.”

The CLIMB SCD-121 trial met primary and key secondary endpoints, with exa-cel treatment resulting in early and sustained increases in Hb and HbF leading to elimination of VOCs in 95% of pts, elimination of inpatient hospitalization for VOCs in 100% of pts and improved QOL. Safety profile of exa‑cel was generally consistent with myeloablative busulfan conditioning and autologous transplantation. These results show exa-cel has the potential to deliver a one-time functional cure to pts with severe SCD.

Exagamglogene autotemcel (exa-cel; Vertex Pharma, CRISPR Therapeutics), recently approved as Casgevy for treating sickle cell disease (SCD), yielded early and sustained increases in Hb and HbF leading to elimination of vaso-occlusive crises in 95% of patients treated in the phase 3 CLIMB SCD121 trial (NCT03745287), which has met its primary and key secondary endpoints.

Updated data from the trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California, by Haydar Frangoul, MD, Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial.

CGTLive spoke with Frangoul to learn more about the new data being presented. He emphasized how the improvements seen in treated patients are clinically meaningful and also touched on quality-of-life improvements presented in an additional poster.

Click here for more coverage of ASH 2023

Frangoul H, Locatelli F, Sharma A, et al. Exagamglogene autotemcel for severe sickle cell disease. Presented at: ASH 2023 Annual Meeting & Exposition. December 9-12; San Diego, CA. Abstract #1052
Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.